Interventional Glaucoma Treatment: Navigating Your Options

For decades, the gold standard for glaucoma management has been a “drops-first” strategy—a cautious, incremental approach designed to lower intraocular pressure (IOP) while delaying surgical intervention. However, a critical paradigm shift is underway. Leading specialists are now arguing that this traditional caution may actually be detrimental, creating a “preservative cycle” that compromises the ocular surface and jeopardizes the success of future surgeries.

The Hidden Cost of Chronic Topical Therapy

The move toward “interventional glaucoma” is driven by an increasing understanding of the biological cost of benzalkonium chloride (BAK). While BAK is an effective preservative, it acts as a detergent that disrupts the tear film and triggers a pro-inflammatory cascade. This isn’t merely a matter of patient discomfort; it is a surgical risk factor.

Chronic subclinical inflammation leads to goblet cell loss and squamous metaplasia. For the clinician, this means that by the time a patient requires a subconjunctival filtration surgery (like a trabeculectomy), the conjunctiva may already be too fibrotic to support a healthy bleb. Essentially, the very medication used to save the optic nerve may be sabotaging the eventual surgical solution.

Navigating the Refractive Minefield

The intersection of glaucoma and cataract surgery presents a complex challenge in IOL selection. The primary conflict is contrast sensitivity. Glaucoma erodes the patient’s ability to distinguish an object from its background—often before visual acuity (Snellen) drops. Trifocal lenses, which split light into multiple foci, further degrade this sensitivity, creating a “double-jeopardy” effect for the patient.

The emergence of non-diffractive EDOF technology, such as the TECNIS PureSee or Vivity, represents a strategic middle ground. These lenses provide a continuous range of vision without the significant contrast loss associated with multifocals, ensuring that the patient’s functional vision remains stable even as the disease progresses.

Redefining the Referral: The Interventional Window

The most significant shift in clinical practice is the recognition of the “Interventional Window.” Rather than waiting for medical therapy to fail, practitioners are now identifying specific “signals” that warrant early surgical referral:

• The Fluctuator: Patients with unstable IOP who would benefit from 24/7 mechanical drainage over inconsistent drop adherence.
• The Surface-Damaged Patient: Those showing punctate keratitis or reduced tear break-up time, where the medication is becoming as harmful as the disease.
• The Steroid Responder: Patients whose IOP spikes due to necessary steroid treatments (e.g., for macular oedema), making them ideal candidates for trabecular bypass.

Forward-Looking Analysis: The Future of Glaucoma Care

We are entering an era of “Refractive-Plus” outcomes. The historical separation between “glaucoma surgery” and “cataract surgery” is collapsing. The ability to perform standalone MIGS—meaning a patient does not need to have cataracts to receive a stent—changes the trajectory of care for the younger, phakic patient.

Looking ahead, we can expect a move toward preventative surgical stabilization. Instead of the “ladder” approach (Step 1: Drop A, Step 2: Drop B, Step 3: Surgery), the model will likely shift toward a “surface-first” assessment. If a patient is identified as highly susceptible to OSD, surgical intervention via trabecular micro-bypass may become the primary line of defense, preserving the ocular surface as a critical asset for the patient’s lifetime visual health.

The ultimate goal is no longer just the stabilization of a number (IOP), but the preservation of the entire ocular environment, ensuring that when the time for refractive surgery eventually arrives, the canvas is pristine.